TY - JOUR
T1 - Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma
T2 - Long-term results
AU - Ghosh-Laskar, Sarbani
AU - Yathiraj, Prahlad H.
AU - Dutta, Debnarayana
AU - Rangarajan, Venkatesh
AU - Purandare, Nilendu
AU - Gupta, Tejpal
AU - Budrukkar, Ashwini
AU - Murthy, Vedang
AU - Kannan, Sadhana
AU - Agarwal, Jai Prakash
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background Grade ≥2 acute xerostomia between 3D conformal radiotherapy (RT) and intensity-modulated radiotherapy (IMRT) was evaluated in patients with head and neck squamous cell carcinomas (HNSCCs) treated radically. Methods Between 2005 and 2007, 59 patients with HNSCC (T1-3, N0-2b) were randomized to IMRT or 3D-RT. On RT, weekly xerostomia, dysphagia, dermatitis, and mucositis were graded by Radiation Therapy Oncology Group (RTOG) acute toxicity criteria. Patients underwent examination under anesthesia, positron emission tomography (PET)-CT, and toxicity assessments per protocol (NCT00652613) thereafter. Results Incidence of grade ≥2 xerostomia at 8 weeks posttreatment was significantly lower with IMRT compared with 3D conformal RT (24% vs 53%; p =.024). At subsequent follow-up, significantly fewer patients receiving IMRT had grade ≥2 xerostomia. Long-term weight loss was higher in patients in the 3D conformal RT arm compared to IMRT (50% vs 21%; p =.038). Disease-related outcomes between arms (median follow-up, 70 months) were similar. Conclusion IMRT significantly reduces incidence of acute and late grade ≥2 xerostomia in patients with HNSCC.
AB - Background Grade ≥2 acute xerostomia between 3D conformal radiotherapy (RT) and intensity-modulated radiotherapy (IMRT) was evaluated in patients with head and neck squamous cell carcinomas (HNSCCs) treated radically. Methods Between 2005 and 2007, 59 patients with HNSCC (T1-3, N0-2b) were randomized to IMRT or 3D-RT. On RT, weekly xerostomia, dysphagia, dermatitis, and mucositis were graded by Radiation Therapy Oncology Group (RTOG) acute toxicity criteria. Patients underwent examination under anesthesia, positron emission tomography (PET)-CT, and toxicity assessments per protocol (NCT00652613) thereafter. Results Incidence of grade ≥2 xerostomia at 8 weeks posttreatment was significantly lower with IMRT compared with 3D conformal RT (24% vs 53%; p =.024). At subsequent follow-up, significantly fewer patients receiving IMRT had grade ≥2 xerostomia. Long-term weight loss was higher in patients in the 3D conformal RT arm compared to IMRT (50% vs 21%; p =.038). Disease-related outcomes between arms (median follow-up, 70 months) were similar. Conclusion IMRT significantly reduces incidence of acute and late grade ≥2 xerostomia in patients with HNSCC.
UR - http://www.scopus.com/inward/record.url?scp=84948163636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948163636&partnerID=8YFLogxK
U2 - 10.1002/hed.24263
DO - 10.1002/hed.24263
M3 - Article
C2 - 26561342
AN - SCOPUS:84948163636
SN - 1043-3074
VL - 38
SP - E1481-E1487
JO - Head and Neck Surgery
JF - Head and Neck Surgery
ER -